Treating severe asthma: Targeting the IL‐5 pathway

Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5 and IL‐13). Monoclonal antibodies that target...

Descripción completa

Detalles Bibliográficos
Autores principales: Principe, Stefania, Porsbjerg, Celeste, Bolm Ditlev, Sisse, Kjærsgaard Klein, Ditte, Golebski, Korneliusz, Dyhre‐Petersen, Nanna, van Dijk, Yoni E., van Bragt, Job J.M.H., Dankelman, Lente L.H., Dahlen, Sven‐Erik, Brightling, Christopher E., Vijverberg, Susanne J.H., Maitland‐van der Zee, Anke H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Invited Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453879/
https://www.ncbi.nlm.nih.gov/pubmed/33887082
http://dx.doi.org/10.1111/cea.13885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453879/
https://www.ncbi.nlm.nih.gov/pubmed/33887082
http://dx.doi.org/10.1111/cea.13885

Ejemplares similares